To more comprehensively assess the pathogenic contribution of the PTEN-PI3K-AKT
pathway to T-cell acute lymphoblastic leukemia (T-ALL), we examined diagnostic DNA …

Leukemia relatively small but significant subset of newly diagnosed T-ALL patient samples
are known to present inactivating PTEN gene mutations. 1–5 PTEN mutation may …

Phosphatase and tensin homolog (PTEN)-inactivating mutations and/or deletions are an
independent risk factor for relapse of T-cell acute lymphoblastic leukemia (T-ALL) patients …

Mutations in the phosphatase and tensin homolog (PTEN) gene leading to PTEN protein
deletion and subsequent activation of the PI3K/Akt signaling pathway are common in …

Background PI3K/AKT pathway mutations are found in T-cell acute lymphoblastic leukemia,
but their overall impact and associations with other genetic aberrations is unknown. PTEN …

Summary Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell
acute lymphoblastic leukemia (T-ALL). Although four distinct class I PI3K isoforms (α, β, γ, δ) …

Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

Phosphorylation of PTEN (phosphatase and tensin homologue) affects PTEN protein
stability and function. In this study, phosphorylated PTEN (pPTEN) was observed in 45 (73 …

Recently, a novel phosphatase designated PTEN/MMAC1/TEP1 and located on
chromosome 10q23. 3 has been implicated as a new tumor suppressor gene in human …

Recently, a putative tumor suppressor gene, PTEN/MMAC1, has been identified at
chromosome 10q23. 3, which encodes a 403 amino acid dual‐specificity phosphatase …